Keros Therapeutics (KROS)
NASDAQ:KROS
KROS Stock Chart & Stats
$10.61
-$0.58(-3.66%)
At close: 4:00 PM EST
$10.61
-$0.58(-3.66%)
Day’s Range― - ―
52-Week Range$9.12 - $22.55
Previous CloseN/A
Volume109.28K
Average Volume (3M)483.21K
Market Cap
$209.20M
Enterprise Value$124.39M
Total Cash (Recent Filing)$287.42M
Total Debt (Recent Filing)$16.88M
Price to Earnings (P/E)8.7
Beta0.87
Next Earnings
Apr 30, 2026EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding19,717,533
10 Day Avg. Volume650,579
30 Day Avg. Volume483,213
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.50
Price to Sales (P/S)3.11
P/FCF Ratio7.15
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue0.51
Enterprise Value/Gross Profit0.51
Enterprise Value/Ebitda1.50
Forecast
1Y Price Target
$22.17Price Target Upside108.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.74
Revenue Forecast (FY)$11.48M
Bulls Say, Bears Say
Bulls Say
Early Clinical DataEarly human results showed increases in lean body mass, larger thigh muscle volume and improvements in bone density and markers, supporting the drug's intended effects on muscle and bone health.
Partnerships And FundingAn exclusive global partnership plus a collaboration with Takeda provide development support and funding that can accelerate programs and free resources to focus on advancing the core rinvatercept program.
Safety ProfileEarly trials reported an acceptable safety profile without dose‑limiting toxicities or serious adverse events, and the molecule appears to reduce interaction with a protein linked to prior bleeding issues, suggesting a lower bleeding risk than earlier activin receptor therapies.
Bears Say
Regulatory UncertaintyUnclear regulatory input on the Phase II study design creates uncertainty about trial acceptability and the potential need for protocol changes that could affect timelines and outcomes.
Safety Signal: Hemoglobin IncreasesDose‑dependent increases in hemoglobin observed in early studies prompted dose reductions and highlight the need for close safety monitoring and possible dosing limitations during further development.
Trial DelaysPostponement of the Phase II trial in Duchenne muscular dystrophy has slowed clinical momentum and could weaken investor confidence in the program's near‑term progress.
Keros Therapeutics News
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $9.12 and its highest was $22.55 in the past 12 months.
What is Keros Therapeutics’s market cap?
Keros Therapeutics’s market cap is $209.20M.
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Apr 30, 2026 which is in 33 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on Mar 04, 2026. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.697 by -$0.163.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate is -1.03.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 19,717,533 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.697. Following the earnings report the stock price went down -14.96%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Currently, no hedge funds are holding shares in KROS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keros Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.17 (108.95% Upside)
$22.17 (108.95% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $254.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.63%
12-Months-Change
Fundamentals
Return on Equity
14.25%
Trailing 12-Months
Asset Growth
-44.33%
Trailing 12-Months
Company Description
Keros Therapeutics
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
KROS Stock 12 Month Forecast
Average Price Target
$22.17
▲(108.95% Upside)
Technical Analysis
Gyre Therapeutics
―
KalVista Pharmaceuticals
―
Palvella Therapeutics
―
Nurix Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
Currently, No data available
---